Lisata Therapeutics(LSTA)
$1.20+0.18 (+17.65%)
LSTA
Lisata Therapeutics financials statements
$1.20
At close:+0.18 (+17.65%)
Want to see LSTA full AI Analyst Report?
Lisata Therapeutics (LSTA) Ratios
1,060 Followers
Lisata Therapeutics Ratios
LSTA's free cash flow for Q2 2026 was $-2.65M. For the 2026 fiscal year, LSTA's free cash flow was increased by $0.00 and operating cash flow was $-2.65M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.76 | 6.16 | 8.18 | 11.26 | 21.27 |
| Quick Ratio | 5.76 | 6.16 | 8.18 | 11.26 | 21.27 |
| Cash Ratio | 5.20 | 2.89 | 3.43 | 5.04 | 5.45 |
| Solvency Ratio | -5.23 | -3.48 | -3.04 | -8.07 | -5.47 |
| Operating Cash Flow Ratio | -5.19 | -3.45 | -3.04 | -3.32 | -4.92 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 14.56M | $ 28.89M | $ 47.12M | $ 65.17M | $ 91.17M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.19 | 1.18 | 1.14 | 1.10 | 1.05 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.02 | 0.02 | 0.09 | 0.19 |
| Net Debt to EBITDA | 0.92 | 0.78 | 0.88 | 0.55 | 0.83 |
| Profitability Margins | |||||
| Gross Profit Margin | 14.12% | 100.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | -10322.35% | -2078.30% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | -10236.47% | -2060.90% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | -10711.18% | -2240.90% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | -10322.35% | -2078.30% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | -9756.47% | -1998.50% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | -9756.47% | -1998.50% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 94.52% | 96.16% | 89.94% | 95.63% | 94.80% |
| EBT Per EBIT | 96.37% | 92.74% | 90.13% | 98.44% | 99.74% |
| Return on Assets (ROA) | -93.47% | -57.10% | -38.10% | -74.25% | -28.31% |
| Return on Equity (ROE) | -111.65% | -67.58% | -43.28% | -81.45% | -29.77% |
| Return on Capital Employed (ROCE) | -124.10% | -76.25% | -53.44% | -86.42% | -31.41% |
| Return on Invested Capital (ROIC) | -117.30% | -72.98% | -47.90% | -82.42% | -29.70% |
| Return on Tangible Assets | -93.47% | -57.41% | -38.29% | -74.59% | -28.31% |
| Earnings Yield | -102.65% | -80.52% | -94.56% | -413.76% | -59.11% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.24 | 1.11 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 9.44 | 13.89 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.01 | 0.03 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.01 | 0.03 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1044.56 | 328.50 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 1502.94 | 328.50 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 2547.50 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 1502.94 | 328.50 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.84 | -2.32 | -2.48 | -4.09 | -6.03 |
| Free Cash Flow Per Share | -1.84 | -2.32 | -2.48 | -4.14 | -6.05 |
| Dividend Paid and CapEx Coverage Ratio | -569.61 | 0.00 | 0.00 | -74.28 | -370.75 |
| Capital Expenditure Coverage Ratio | -569.61 | 0.00 | 0.00 | -74.28 | -370.75 |
| Operating Cash Flow Coverage Ratio | 0.00 | -141.28 | -119.24 | -43.65 | -31.16 |
| Operating Cash Flow to Sales Ratio | -93.82 | -19.36 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -98.88% | -77.98% | -90.89% | -163.71% | -48.00% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.97 | -1.24 | -1.06 | -0.24 | -1.69 |
| Price-to-Sales (P/S) Ratio | 95.05 | 24.82 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.09 | 0.84 | 0.46 | 0.20 | 0.50 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.01 | -1.28 | -1.10 | -0.61 | -2.08 |
| Price-to-Operating Cash Flow Ratio | -1.01 | -1.28 | -1.10 | -0.62 | -2.09 |
| Price-to-Earnings Growth (PEG) Ratio | 0.05 | 0.18 | 0.01 | -0.01 | 0.29 |
| Enterprise Value Multiple | -0.01 | -0.42 | 0.02 | 0.32 | -0.78 |
| Enterprise Value | 201.82K | 8.75M | -385.71K | -18.56M | 22.54M |
| EV to EBITDA | -0.01 | -0.42 | 0.02 | 0.32 | -0.78 |
| EV to Sales | 1.19 | 8.75 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.01 | -0.45 | 0.02 | 0.87 | -1.01 |
| EV to Operating Cash Flow | -0.01 | -0.45 | 0.02 | 0.88 | -1.01 |
| Tangible Book Value Per Share | 1.68 | 3.50 | 5.90 | 12.74 | 24.95 |
| Shareholders’ Equity Per Share | 1.71 | 3.55 | 5.96 | 12.85 | 25.01 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.05 | 0.04 | 0.10 | 0.04 | 0.05 |
| Revenue Per Share | 0.02 | 0.12 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.91 | -2.40 | -2.58 | -10.47 | -7.45 |
| Tax Burden | 0.95 | 0.96 | 0.90 | 0.96 | 0.95 |
| Interest Burden | 1.00 | 1.00 | 0.90 | 0.98 | 1.00 |
| Research & Development to Revenue | 46.76 | 11.33 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 61.35 | 12.07 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 7.21 | 1.65 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.96 | 0.97 | 0.96 | 0.39 | 0.81 |
Currency in USD
